skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 39  for All Library Resources

Results 1 2 next page
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Material Type:
Article
Add to My Research

Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis

Research and Practice in Thrombosis and Haemostasis, 2020-10, Vol.4 (7), p.1178-1191 [Peer Reviewed Journal]

2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). ;2020 The Authors. published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). ;2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2475-0379 ;EISSN: 2475-0379 ;DOI: 10.1002/rth2.12439 ;PMID: 33043231

Digital Resources/Online E-Resources

2
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy
Material Type:
Article
Add to My Research

Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy

Blood, 2021-03, Vol.137 (12), p.1669-1678 [Peer Reviewed Journal]

2021 American Society of Hematology ;2021 by The American Society of Hematology. ;2021 by The American Society of Hematology 2021 ;ISSN: 0006-4971 ;EISSN: 1528-0020 ;DOI: 10.1182/blood.2020007878 ;PMID: 33067632

Full text available

3
Cancer-associated venous thromboembolism
Material Type:
Article
Add to My Research

Cancer-associated venous thromboembolism

Nature reviews. Disease primers, 2022-02, Vol.8 (1), p.11-11, Article 11 [Peer Reviewed Journal]

2022. Springer Nature Limited. ;Springer Nature Limited 2022. ;ISSN: 2056-676X ;EISSN: 2056-676X ;DOI: 10.1038/s41572-022-00336-y ;PMID: 35177631

Full text available

4
Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials
Material Type:
Article
Add to My Research

Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials

Research and practice in thrombosis and haemostasis, 2020-05, Vol.4 (4), p.550-561 [Peer Reviewed Journal]

2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis. ;2020 The Authors. published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis. ;2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 2475-0379 ;EISSN: 2475-0379 ;DOI: 10.1002/rth2.12359 ;PMID: 32548553

Full text available

5
Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer
Material Type:
Article
Add to My Research

Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer

International journal of molecular sciences, 2022-12, Vol.23 (24), p.15770 [Peer Reviewed Journal]

2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 by the authors. 2022 ;ISSN: 1661-6596 ;EISSN: 1422-0067 ;DOI: 10.3390/ijms232415770 ;PMID: 36555414

Full text available

6
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
Material Type:
Article
Add to My Research

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis

Scientific reports, 2019-04, Vol.9 (1), p.5548, Article 5548 [Peer Reviewed Journal]

The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-019-42069-1 ;PMID: 30944390

Full text available

7
Risk assessment for recurrent venous thromboembolism in patients with cancer
Material Type:
Article
Add to My Research

Risk assessment for recurrent venous thromboembolism in patients with cancer

Thrombosis update, 2021-12, Vol.5, p.100080, Article 100080 [Peer Reviewed Journal]

2021 The Authors ;ISSN: 2666-5727 ;EISSN: 2666-5727 ;DOI: 10.1016/j.tru.2021.100080

Full text available

8
Risk assessment models of cancer-associated thrombosis - Potentials and perspectives
Material Type:
Article
Add to My Research

Risk assessment models of cancer-associated thrombosis - Potentials and perspectives

Thrombosis update, 2021-12, Vol.5, p.100075, Article 100075 [Peer Reviewed Journal]

2021 The Authors ;ISSN: 2666-5727 ;EISSN: 2666-5727 ;DOI: 10.1016/j.tru.2021.100075

Full text available

9
Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability
Material Type:
Article
Add to My Research

Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability

Cancers, 2021-05, Vol.13 (9), p.2260 [Peer Reviewed Journal]

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 by the authors. 2021 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers13092260 ;PMID: 34066760

Full text available

10
Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism
Material Type:
Article
Add to My Research

Outpatient Pulmonary Rehabilitation in Patients with Persisting Symptoms after Pulmonary Embolism

Journal of clinical medicine, 2020-06, Vol.9 (6), p.1811 [Peer Reviewed Journal]

2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm9061811 ;PMID: 32532020

Full text available

11
Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy
Material Type:
Article
Add to My Research

Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy

Scientific reports, 2020-07, Vol.10 (1), p.11219, Article 11219 [Peer Reviewed Journal]

The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2020 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-020-68010-5 ;PMID: 32641710

Full text available

12
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer
Material Type:
Article
Add to My Research

Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer

Blood advances, 2021-01, Vol.5 (2), p.487-495 [Peer Reviewed Journal]

2021 The American Society of Hematology ;2021 by The American Society of Hematology. ;2021 by The American Society of Hematology 2021 ;ISSN: 2473-9529 ;EISSN: 2473-9537 ;DOI: 10.1182/bloodadvances.2020003149 ;PMID: 33496742

Full text available

13
Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study
Material Type:
Article
Add to My Research

Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study

Cancers, 2020-09, Vol.12 (9), p.2493 [Peer Reviewed Journal]

COPYRIGHT 2020 MDPI AG ;2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 by the authors. 2020 ;ISSN: 2072-6694 ;EISSN: 2072-6694 ;DOI: 10.3390/cancers12092493 ;PMID: 32899157

Full text available

14
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic
Material Type:
Article
Add to My Research

SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic

ESMO Open, 2020-09, Vol.5 (5), p.e000889-e000889, Article e000889 [Peer Reviewed Journal]

Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. ;2020 © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. ;2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. 2020 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1136/esmoopen-2020-000889 ;PMID: 32878898

Digital Resources/Online E-Resources

15
Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer
Material Type:
Article
Add to My Research

Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer

Frontiers in cardiovascular medicine, 2022-08, Vol.9, p.933428-933428 [Peer Reviewed Journal]

Copyright © 2022 Posch, Niedrist, Glantschnig, Firla, Moik, Kolesnik, Wallner, Verheyen, Jost, Zirlik, Pichler, Balic and Rainer. 2022 Posch, Niedrist, Glantschnig, Firla, Moik, Kolesnik, Wallner, Verheyen, Jost, Zirlik, Pichler, Balic and Rainer ;ISSN: 2297-055X ;EISSN: 2297-055X ;DOI: 10.3389/fcvm.2022.933428 ;PMID: 36051281

Full text available

16
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study
Material Type:
Article
Add to My Research

Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study

Journal for immunotherapy of cancer, 2023-12, Vol.11 (12), p.e007765 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. ;2023 Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2023 ;ISSN: 2051-1426 ;EISSN: 2051-1426 ;DOI: 10.1136/jitc-2023-007765 ;PMID: 38097343

Full text available

17
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma
Material Type:
Article
Add to My Research

Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma

ESMO open, 2020-05, Vol.5 (3), p.e000647-e000647, Article e000647 [Peer Reviewed Journal]

Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. ;2020 © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. ;Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. 2020 ;ISSN: 2059-7029 ;EISSN: 2059-7029 ;DOI: 10.1136/esmoopen-2019-000647 ;PMID: 32424065

Full text available

18
VTE with Amivantamab plus Chemotherapy in NSCLC
Material Type:
Article
Add to My Research

VTE with Amivantamab plus Chemotherapy in NSCLC

The New England journal of medicine, 2024-02, Vol.390 (6), p.578-580 [Peer Reviewed Journal]

Copyright © 2024 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMc2314937 ;PMID: 38324502

Full text available

19
Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life
Material Type:
Article
Add to My Research

Outpatient Pulmonary Rehabilitation in Patients with Long COVID Improves Exercise Capacity, Functional Status, Dyspnea, Fatigue, and Quality of Life

Respiration, 2022-06, Vol.101 (6), p.593-601 [Peer Reviewed Journal]

2022 The Author(s). Published by S. Karger AG, Basel ;2022. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. ;ISSN: 0025-7931 ;EISSN: 1423-0356 ;DOI: 10.1159/000522118 ;PMID: 35203084

Digital Resources/Online E-Resources

20
Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer
Material Type:
Article
Add to My Research

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Haematologica (Roma), 2024-04, Vol.109 (4), p.1128-1136 [Peer Reviewed Journal]

Copyright© 2024 Ferrata Storti Foundation ;ISSN: 0390-6078 ;EISSN: 1592-8721 ;DOI: 10.3324/haematol.2023.283581 ;PMID: 37822244

Full text available

Results 1 - 20 of 39  for All Library Resources

Results 1 2 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (38)

Refine My Results

Creation Date 

From To
  1. Before 2017  (1)
  2. 2017 To 2018  (3)
  3. 2019 To 2019  (3)
  4. 2020 To 2021  (18)
  5. After 2021  (15)
  6. More options open sub menu

Searching Remote Databases, Please Wait